Interferon-alpha, immune activation and immune dysfunction in treated HIV infection - Test2 - elhamkhani - TriplyDB

Interferon-alpha, immune activation and immune dysfunction in treated HIV infection

Interferon-alpha, immune activation and immune dysfunction in treated HIV infection

http://www.wikidata.org/entity/Q26861003

about

Immune Activation Influences SAMHD1 Expression and Vpx-mediated SAMHD1 Degradation during Chronic HIV-1 Infection Role of the immune system in HIV-associated neuroinflammation and neurocognitive implications.New insights into type I interferon and the immunopathogenesis of persistent viral infections.HIV-1 Env and Nef Cooperatively Contribute to Plasmacytoid Dendritic Cell Activation via CD4-Dependent Mechanisms Dysregulated Immune Activation in Second-Line HAART HIV+ Patients Is Similar to That of Untreated Patients.Integrative Analysis of Immunological Data to Explore Chronic Immune T-Cell Activation in Successfully Treated HIV Patients.APOBEC3 proteins can copackage and comutate HIV-1 genomes.HIV Maintains an Evolving and Dispersed Population in Multiple Tissues during Suppressive Combined Antiretroviral Therapy in Individuals with Cancer.HIV-TB co-infection: mechanisms that drive reactivation of Mycobacterium tuberculosis in HIV infection.Immune Response and Mortality Risk Relate to Distinct Lung Microbiomes in Patients with HIV and Pneumonia.Δ9-Tetrahydrocannabinol Suppresses Secretion of IFNα by Plasmacytoid Dendritic Cells From Healthy and HIV-Infected Individuals.Greater decline in memory and global neurocognitive function in HIV/hepatitis C co-infected than in hepatitis C mono-infected patients treated with pegylated interferon and ribavirin.Interferon Alpha Subtype-Specific Suppression of HIV-1 Infection In Vivo.Immune activated monocyte exosomes alter microRNAs in brain endothelial cells and initiate an inflammatory response through the TLR4/MyD88 pathway.Control of HIV infection by IFN-α: implications for latency and a cure.HIV-infected cannabis users have lower circulating CD16+ monocytes and IP-10 levels compared to non-using HIV patients.Sustained IFN-I Expression during Established Persistent Viral Infection: A "Bad Seed" for Protective Immunity.Antiretroviral Drugs Alter the Content of Extracellular Vesicles from HIV-1-Infected Cells.Induction of Type I Interferons by Therapeutic Nanoparticle-Based Vaccination Is Indispensable to Reinforce Cytotoxic CD8+ T Cell Responses During Chronic Retroviral Infection."Toll-free" pathways for production of type I interferons

P2860

Q28589591-0C745DBF-0108-4DAF-A2E0-C19F05F870DF Q35125996-282FF810-F228-4285-B411-72953B151185 Q35648751-AD1609F2-7A29-4E35-A706-7C8F9F05920F Q35861175-F9796596-918A-408E-B00D-F62C2A0D37FE Q35873402-54A8DED9-E3C9-47A6-A039-589DD10C3023 Q36238363-E84DD864-0784-40DB-AFC5-E868B5769BB3 Q37264399-9EEC0622-64AB-4FC3-A711-BB947D297905 Q37300442-02CAB966-4DDB-4743-A7F1-72976677173C Q38816188-D79FB9D1-B433-48E2-9B86-0B14EC36A92B Q38853678-3CFFE7D2-C382-4632-A398-8C6630662ED5 Q40129268-673F00C3-568B-4AFE-B30E-6143B20D4746 Q40431770-73045F5B-096F-4097-9EE2-24D9144C544D Q40705563-920F7A4D-F0A4-471D-9D8B-A064A3EEC6C1 Q41564855-27BD2BF5-9C62-4F89-A646-BAB9FCEC3F6B Q41922021-82DB5AFF-5654-4298-9356-1CA108D53BFF Q47342684-82C5823A-AAF9-42B0-BFC3-822AE0438DCA Q47558114-60026111-3E11-46F0-9F98-629729107195 Q54209535-76C90AF0-4097-4649-864F-C51B93D810A7 Q54217623-5120FB7B-34BA-47E7-8FF1-4BF3E0725985 Q57018017-18EDB422-549C-4272-9D89-CA17E9C4F996

P2860

Interferon-alpha, immune activation and immune dysfunction in treated HIV infection

http://www.wikidata.org/entity/Q26861003

description

2014 nî lūn-bûn

@nan

2014 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Interferon-alpha, immune activation and immune dysfunction in treated HIV infection

@ast

Interferon-alpha, immune activation and immune dysfunction in treated HIV infection

@en

Interferon-alpha, immune activation and immune dysfunction in treated HIV infection

@nl

type

label

Interferon-alpha, immune activation and immune dysfunction in treated HIV infection

@ast

Interferon-alpha, immune activation and immune dysfunction in treated HIV infection

@en

Interferon-alpha, immune activation and immune dysfunction in treated HIV infection

@nl

prefLabel

Interferon-alpha, immune activation and immune dysfunction in treated HIV infection

@ast

Interferon-alpha, immune activation and immune dysfunction in treated HIV infection

@en

Interferon-alpha, immune activation and immune dysfunction in treated HIV infection

@nl

P1433

Q26861003-3991365D-F809-4E2D-8746-7789D503C2DF

P1476

Q26861003-F486904A-C2DD-48F0-88A7-0A8194C5CD39

P2093

Q26861003-22D65E7B-B582-408D-BBCF-73D12F767199

Q26861003-6EBA467D-109D-4F3D-9E8C-0E4B7DF53342

Q26861003-E517DF1D-8B07-4550-9A79-E2700F368CDA

Q26861003-E9364DA1-CC8A-4E6A-BC1A-48677E9FC980

P2860

Q26861003-03061C74-8D45-4F50-9005-D7641F725689

Q26861003-175CC01B-07B8-4F40-A6C2-5B84BECE9A90

Q26861003-1888648A-D6B5-4642-B1B2-65AFFBD66549

Q26861003-19C27A48-E8C7-4332-B4BE-3110E381ECC0

Q26861003-1A68A3C6-8189-4A1C-8491-F8479DE3E074

Q26861003-1AF7CA30-16D1-4A8A-8AE8-DF2F8CB5FCE4

Q26861003-1D0C0381-D0D0-43AE-AE0B-C53E66C59127

Q26861003-26DB282F-C236-4322-A9B8-6B2F323FDB9B

Q26861003-2FA419D8-9343-42ED-9CAC-9B0899AAD66C

Q26861003-31075B0B-EA2D-4D44-8FFE-918A3E89839A

P304

Q26861003-BAEFD955-CB31-420F-92BA-9BBE78AB0AF9

P31

Q26861003-FAA17EE8-11CA-47EE-BAA2-7AF94CD34ACB

P3181

Q26861003-5E4652BF-6D89-4CFB-91D0-95F5468145B4

P356

Q26861003-FA31D96A-44AA-4F3E-BBF4-79D3FE352951

P407

Q26861003-41D81E2B-CB9E-40F7-B179-B7F106F412E5

P433

Q26861003-8ADA3EC6-6C53-4D6C-AC81-83859B6D7F08

P478

Q26861003-6C2F2011-9183-44C3-AC9C-21745B94B49B

P50

Q26861003-20FBAECB-A926-4D62-B74E-AC03835A04E7

Q26861003-37FE8250-8F11-461E-A1B2-0368DE97FCFE

P577

Q26861003-DF49FE9A-CE2F-479C-AEB3-870D0F7E8E27

P5875

Q26861003-A88F81B3-38AD-452D-B5B2-08D8594489AC

P698

Q26861003-78DC30CC-70DA-4A49-83AB-1D4F47ED7579

P932

Q26861003-5E6BBE74-F5B6-4C90-86A0-B02003BD7775

P3181

P356

P1433

Clinical & translational immunology

P1476

Interferon-alpha, immune activation and immune dysfunction in treated HIV infection

@en

P2093

Allison Castley

http://www.w3.org/2001/XMLSchema#string

Cassandra M Berry

http://www.w3.org/2001/XMLSchema#string

David Nolan

http://www.w3.org/2001/XMLSchema#string

Lilian Cha

http://www.w3.org/2001/XMLSchema#string

P2860

Human MX2 is an interferon-induced post-entry inhibitor of HIV-1 infection

MX2 is an interferon-induced inhibitor of HIV-1 infection

A diverse range of gene products are effectors of the type I interferon antiviral response

Constitutive type I interferon modulates homeostatic balance through tonic signaling

Type I interferon: friend or foe?

A plasma biomarker signature of immune activation in HIV patients on antiretroviral therapy

Cloning and characterization of soluble and transmembrane isoforms of a novel component of the murine type I interferon receptor, IFNAR 2

Anti-retroviral effects of type I IFN subtypes in vivo

Impact of HIV on cell survival and antiviral activity of plasmacytoid dendritic cells

HIV-induced type I interferon and tryptophan catabolism drive T cell dysfunction despite phenotypic activation

P304

e10

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

4477731

http://www.w3.org/2001/XMLSchema#string

P356

10.1038/CTI.2014.1

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

3

http://www.w3.org/2001/XMLSchema#string

P50

Sonia Fernandez

Martyn A. French

P577

2014-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

260555357

http://www.w3.org/2001/XMLSchema#string

P698

25505958

http://www.w3.org/2001/XMLSchema#string

P932

4232062

http://www.w3.org/2001/XMLSchema#string